Schizophrenia News and Research

Latest Schizophrenia News and Research

IntegraGen now offers Fluidigm's IFC technology to French researchers

Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France’s leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen’s lab will also be a demonstration site for researchers investigating Fluidigm’s technology.

25 Jan 2010

Consistent pattern of cognitive deficits during childhood leads to adult schizophrenia

Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed.

22 Jan 2010

New blood test for diagnosing schizophrenia to be launched in 2010

A blood test for diagnosing schizophrenia - the most serious form of mental illness - could be available this year, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

21 Jan 2010

Tel Aviv University finds estrogen may protect women from psychosis

Many American women are prescribed estrogen to combat the negative effects of menopause, such as bone loss and mood swings. Now, new evidence from a Tel Aviv University study suggests that hormone replacement therapy might also protect them ― and younger women ― from schizophrenia as well.

21 Jan 2010

Study shows an intriguing relationship between cancer-related genes and schizophrenia susceptibility

People who inherit a specific form of a gene that puts them on a road to schizophrenia may be protected against some forms of cancer, according to a new study by scientists at The Feinstein Institute for Medical Research.

20 Jan 2010

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression.

19 Jan 2010

Study reveals link between serotonin receptor number and antidepressant treatment

An excess of one type of serotonin receptor in the center of the brain may explain why antidepressants fail to relieve symptoms of depression for 50 percent of patients, a new study from researchers at Columbia University Medical Center shows.

18 Jan 2010

Metabolon awarded US Patent for ‘metabolomics methods’

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, today announced that it was awarded US Patent 7,635,556 “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics” by the United States Patent and Trademark Office on December 22, 2009.

18 Jan 2010

Majority of doctors appear to ignore FDA warning to screen high-risk medications

A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general.

13 Jan 2010

Scientists identify fast-acting compound to improve cognitive function impairments

A fast-acting compound that appears to improve cognitive function impairments in mice similar to those found in patients with progressive Alzheimer's disease has been identified by scientists at Wake Forest University School of Medicine and the Vanderbilt University Medical Center Program in Drug Discovery.

13 Jan 2010

GAO: Some meds had 'extraordinary' price hikes over past eight years

A report from the Government Accountability Office (GAO) issued Monday finds that "[p]rices on a growing number of prescription medications have ballooned in recent years as consolidation in the drug industry leaves fewer companies manufacturing niche medications," The Associated Press reports.

12 Jan 2010

Prescribing culture of antipsychotic medications in nursing homes examined

Older adults newly admitted to nursing homes with high rates of antipsychotic prescribing in the previous year are more likely to receive antipsychotic agents, according to a report in the January 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Of these treated patients, some had no identified clinical indication for this therapy.

12 Jan 2010

Ongoing pressures of human evolution could explain rise in disorders; scientists call for broader perspective

The subtle but ongoing pressures of human evolution could explain the seeming rise of disorders such as autism, autoimmune diseases, and reproductive cancers, researchers write in the Proceedings of the National Academy of Sciences.

12 Jan 2010

Targacept signs collaboration and license agreement with AstraZeneca

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its collaboration and license agreement with AstraZeneca for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

11 Jan 2010

U-M study reveals black men are misdiagnosed with schizophrenia five times higher than any other group

Black men are over-diagnosed with schizophrenia at least five times higher than any other group--a trend that dates back to the 1960s, according to new University of Michigan research.

7 Jan 2010

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.

6 Jan 2010

Perturbing DISC1 gene could help researchers treat mental illness, says study

Scientists have long eyed mutations in a gene known as DISC1 as a possible contributor to schizophrenia and mood disorders, including depression and bipolar disorder. Now, new research led by Johns Hopkins researchers suggests that perturbing this gene during prenatal periods, postnatal periods or both may have different effects in mice, leading to separate types of brain alterations and behaviors with resemblance to schizophrenia or mood disorders.

6 Jan 2010

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx’s novel anticoagulant agent, tecarfarin (ATI-5923).

5 Jan 2010

DSPA submits lurasidone NDA to the FDA

Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes data from more than 40 clinical studies involving more than 2,500 lurasidone-treated patients.

4 Jan 2010

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects. According to the paper, the researchers established the structural basis of PDE4 regulation through crystal structures of the PDE4 regulatory domain in contact with small molecules.

29 Dec 2009

Schizophrenia News and Research

Latest Schizophrenia News and Research

IntegraGen now offers Fluidigm's IFC technology to French researchers

Consistent pattern of cognitive deficits during childhood leads to adult schizophrenia

New blood test for diagnosing schizophrenia to be launched in 2010

Tel Aviv University finds estrogen may protect women from psychosis

Study shows an intriguing relationship between cancer-related genes and schizophrenia susceptibility

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

Study reveals link between serotonin receptor number and antidepressant treatment

Metabolon awarded US Patent for ‘metabolomics methods’

Majority of doctors appear to ignore FDA warning to screen high-risk medications

Scientists identify fast-acting compound to improve cognitive function impairments

GAO: Some meds had 'extraordinary' price hikes over past eight years

Prescribing culture of antipsychotic medications in nursing homes examined

Ongoing pressures of human evolution could explain rise in disorders; scientists call for broader perspective

Targacept signs collaboration and license agreement with AstraZeneca

U-M study reveals black men are misdiagnosed with schizophrenia five times higher than any other group

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

Perturbing DISC1 gene could help researchers treat mental illness, says study

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

DSPA submits lurasidone NDA to the FDA

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Schizophrenia News and Research

Latest Schizophrenia News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in